TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33471739

Group type: EXPERIMENTAL
Intervention: No oral calcium or calcitriol supplementation (test group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral calcium and calcitriol supplementation (control group)
Number of subjects: 56
Study: 35508349

Group type: EXPERIMENTAL
Intervention: Deferred consent procedures in the ACROBAT pilot trial
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recruitment process by research midwives and clinical trials practitioners
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Communication of trial information to women
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Participant information complexity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concerns regarding deferred consent procedures
Number of subjects: 10
Study: 33909896

Group type: EXPERIMENTAL
Intervention: Weight-shifting exercise to the nonparetic side on an inclined surface (5 degrees)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group performed the exercise on a flat surface
Number of subjects: 52
Study: 35887534

Group type: EXPERIMENTAL
Intervention: DehydraTECH2.0 CBD formulation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 36239048

Group type: EXPERIMENTAL
Intervention: imeglimin
Number of subjects: 59
Study: 32046199

Group type: EXPERIMENTAL
Intervention: Pre‐emptive analgesia, multimodal analgesia, and analgosedation
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Drugs administered on demand
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Drugs from Steps 2 and 3 of the WHO analgesic ladder
Number of subjects: 216
Study: 32965464

Group type: EXPERIMENTAL
Intervention: Escalating financial incentives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deescalating financial incentives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no incentive)
Number of subjects: 0
Study: 32026297

Group type: EXPERIMENTAL
Intervention: 0.5% centbucridine
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 56
Study: 35901040

Group type: EXPERIMENTAL
Intervention: Affect School intervention
Number of subjects: 9
Study: 34380322

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 2185
Study: 32365226

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg weekly) plus Cetuximab (400/250 mg/m2 weekly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Temsirolimus alone
Number of subjects: 80
Study: 35395734

Group type: EXPERIMENTAL
Intervention: Needs-based education program (5 sessions)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 86
Study: 33089943

Group type: EXPERIMENTAL
Intervention: Education group (I)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Education + SMS group (I)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 185
Study: 33977342

Group type: EXPERIMENTAL
Intervention: Interventionist-guided (IG) weight loss intervention
Number of subjects: 246

Group type: COMPARATOR
Intervention: Self-guided (SG) weight loss intervention
Number of subjects: 246
Study: 32030780

Group type: EXPERIMENTAL
Intervention: A annua sublingual immunotherapy (SLIT) for 32 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: A annua sublingual immunotherapy (SLIT) for 16 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: A annua sublingual immunotherapy (SLIT)
Number of subjects: 71
Study: 36297099

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (HDIVC)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 32111126

Group type: EXPERIMENTAL
Intervention: 3-D system for treating macular holes (MH)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 3-D system for treating primary rhegmatogenous retinal detachment (RRD)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Traditional microscopy for treating macular holes (MH)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ocular viewing for treating primary RRD
Number of subjects: 4
Study: 36151448

Group type: EXPERIMENTAL
Intervention: Sound therapy combined with drug therapy (SDT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Drug therapy (DT)
Number of subjects: 44
Study: 33641346

Group type: EXPERIMENTAL
Intervention: LT-5%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Delta50
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MLSS-5%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MLSSp
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MLSS+5%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MLSS15
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MLSS45
Number of subjects: 11
Study: 32285195

Group type: EXPERIMENTAL
Intervention: Usual care enhanced with ultrasound measurements of the diaphragm
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined Intervention and Control groups
Number of subjects: 32
Study: 35867135

Group type: EXPERIMENTAL
Intervention: High albumin + IVIG treatment group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo (sham PE)
Number of subjects: 198
Study: 34369618

Group type: EXPERIMENTAL
Intervention: Tailored mindfulness-based program (MBP) for resident physicians; 8-week intervention followed by a 4-month maintenance phase.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Active control group received the coursebook for self-study.
Number of subjects: 147
Study: 36173046

Group type: EXPERIMENTAL
Intervention: Palliative home visit intervention (3-month program, 6 sessions, 1 session every 2 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no home visit intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Palliative home visit intervention
Number of subjects: 60
Study: 33958216

Group type: EXPERIMENTAL
Intervention: Telehealth visits
Number of subjects: 200

Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 200
Study: 32868350

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 181
Study: 35513899

Group type: EXPERIMENTAL
Intervention: Once-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Once-daily fixed combination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Twice-daily fixed combination
Number of subjects: 30
Study: 34849580

Group type: EXPERIMENTAL
Intervention: Native recipient portal vein (RPV)
Number of subjects: 122

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both RPV and PTFE
Number of subjects: 122
Study: 34585482

Group type: EXPERIMENTAL
Intervention: SlowMo intervention (eight‐session digitally supported reasoning intervention)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: PPI involvement
Number of subjects: 362
Study: 32035516

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E and ALVAC-HIV (vCP1521) at month 12
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E alone at month 12
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E and ALVAC-HIV at month 15
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E and ALVAC-HIV at month 18
Number of subjects: 367

Group type: COMPARATOR
Intervention: No late boost (group 1)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Delayed boosting (groups 2, 3, 4a, and 4b)
Number of subjects: 367
Study: 35150194

Group type: EXPERIMENTAL
Intervention: Technique A (shallow injection/3 aliquots)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Technique D (deep and shallow injections/5 aliquots)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Techniques A, D, and E
Number of subjects: 63
Study: 33549750

Group type: EXPERIMENTAL
Intervention: Self-perceived physical health QoL
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Self-perceived daily living activities
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Self-perceived pain and discomfort
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Global neuroimaging values
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Voxel-wise analyses
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Correction for objective physical health and physical activity measures
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Global brain perfusion and global amyloid deposition
Number of subjects: 135
Study: 32665479

Group type: EXPERIMENTAL
Intervention: PP-MI intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: MI-enhanced behavioral counseling
Number of subjects: 60
Study: 616562397

Group type: EXPERIMENTAL
Intervention: Pre-cooling by means of water immersion (20.3 ± 0.3°C) for 60 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition: remained seated for 60 min in a laboratory (20.2 ± 1.7°C and 60.2 ± 2.5% r.h.)
Number of subjects: 8
Study: 33794353

Group type: EXPERIMENTAL
Intervention: Web-based Drug Management Module (DMM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Manual process
Number of subjects: 34
Study: 32067629

Group type: EXPERIMENTAL
Intervention: Biannual single-dose azithromycin
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 34087948

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (OM) 25 mg modified release (MR) tablets under fed state
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (OM) 37.5 mg modified release (MR) tablets under fed state
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (OM) 50 mg modified release (MR) tablets under fed state
Number of subjects: 73

Group type: COMPARATOR
Intervention: Two 25 mg OM MR tablets
Number of subjects: 73
Study: 34922039

Group type: EXPERIMENTAL
Intervention: Separated action effects (action-effect condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjoined error feedback (feedback condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task condition (baseline condition)
Number of subjects: 0
Study: 35714786

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 2583

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2583
Study: 36261162

Group type: EXPERIMENTAL
Intervention: Financial voucher incentives (up to £400) in addition to usual support from stop smoking services
Number of subjects: 944

Group type: COMPARATOR
Intervention: Standard stop smoking services (control group)
Number of subjects: 944
Study: 33652234

Group type: EXPERIMENTAL
Intervention: Microwave heating
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autoclave heating
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no thermal treatment)
Number of subjects: 30
Study: 33444175

Group type: EXPERIMENTAL
Intervention: I-WOTCH multicomponent self-management intervention for tapering opioid doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best usual care
Number of subjects: 0
Study: 34600734

Group type: EXPERIMENTAL
Intervention: BDP/FF/GB 200/12/25 ?g (therapeutic)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BDP/FF/GB 400/12/25 ?g (therapeutic)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: BDP/FF/GB 800/48/100 ?g (supratherapeutic)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 32382772

Group type: EXPERIMENTAL
Intervention: Carfilzomib-based regimen
Number of subjects: 2954

Group type: COMPARATOR
Intervention: Non-carfilzomib-based regimen
Number of subjects: 2954
Study: 34168284

Group type: EXPERIMENTAL
Intervention: ixazomib-dexamethasone
Number of subjects: 168

Group type: COMPARATOR
Intervention: physician’s choice
Number of subjects: 168
Study: 34534429

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) plus platinum-based chemotherapy (with or without bevacizumab)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (with or without bevacizumab)
Number of subjects: 548
Study: 32892710

Group type: EXPERIMENTAL
Intervention: Bayesian sample size calculation for snSMART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frequentist method based on a weighted Z-statistic
Number of subjects: 0
Study: 36427174

Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 34419135

Group type: EXPERIMENTAL
Intervention: WeChat follow-up management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 100
Study: 32131641

Group type: EXPERIMENTAL
Intervention: patisiran 0.3 mg/kg
Number of subjects: 225

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 225
Study: 35305154

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided methodologic approach (UMA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Classical pubic approach (PA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Inguinal approach (IA)
Number of subjects: 143
Study: 34584851

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral therapy (ICBT), guided self-help tailored to predominant symptomatology of PTSD or depression, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control condition, received delayed treatment at follow-up assessment.
Number of subjects: 0
Study: 33142129

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Binge-eating disorder (BED)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Avoidant-restrictive food intake disorder (ARFID)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Restrained eating
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Picky eating
Number of subjects: 1147
Study: 36307177

Group type: EXPERIMENTAL
Intervention: Over-the-scope clip (OTSC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study: 32713721

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) with a hypoenergetic diet for 12 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hypoenergetic diet only for 12 months
Number of subjects: 58
Study: 32299222

Group type: EXPERIMENTAL
Intervention: FFR-guided rate-adaptive pacing
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional age-guided rate-response programming
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: FFR-guided heart rate settings
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional settings
Number of subjects: 83
Study: 35915056

Group type: EXPERIMENTAL
Intervention: One Session Treatment (OST)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Multi-session Cognitive Behavioral Therapy (CBT)
Number of subjects: 268
Study: 34403591

Group type: EXPERIMENTAL
Intervention: MindLight
Number of subjects: 117

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 117
Study: 32482712

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR) for 3 months followed by a 4-week weight maintenance phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stable weight maintenance (Control group)
Number of subjects: 0
Study: 35752762

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) group (n=31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) group (n=31)
Number of subjects: 62
Study: 35292074

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion on the navel once a week for three consecutive menstrual cycles
Number of subjects: 210

Group type: COMPARATOR
Intervention: No intervention (control group) for 3 menstrual cycles
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion on the navel
Number of subjects: 210

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 210
Study: 34556318

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33452406

Group type: EXPERIMENTAL
Intervention: 45°-tilt view
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 45°-rotation plus 45°-tilt view
Number of subjects: 49

Group type: COMPARATOR
Intervention: Neutral view
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 45°-rotation view
Number of subjects: 49
Study: 34689182

Group type: EXPERIMENTAL
Intervention: PPCCC group
Number of subjects: 56

Group type: COMPARATOR
Intervention: NPCCC group
Number of subjects: 56
Study: 34580500

Group type: EXPERIMENTAL
Intervention: Wii Fit gaming
Number of subjects: 90

Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 90
Study: 32222589

Group type: EXPERIMENTAL
Intervention: Cilostazol and aspirin
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Cilostazol administration
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: New-AF group
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Non-AF group
Number of subjects: 1194
Study: 34304054

Group type: EXPERIMENTAL
Intervention: S-1 and irinotecan plus bevacizumab (experimental group)
Number of subjects: 487

Group type: COMPARATOR
Intervention: mFOLFOX6/CapeOX plus bevacizumab (control group)
Number of subjects: 487
Study: 32674792

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg daily prior to completion of gestational week 10, maintained through pregnancy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone (after excluding 9 mothers on confounding medications)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 54
Study: 35605625

Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·1 mL)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·2 mL)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Homologous intramuscular vaccination with CoronaVac (0·5 mL)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV
Number of subjects: 420

Group type: COMPARATOR
Intervention: Homologous intramuscular vaccination with CoronaVac
Number of subjects: 420
Study: 33087480

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DexM) 2 µg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 35109880

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 3 bouts of 9-min intervals at 90% of HRmax, interspersed by 1 min rest, 5 days a week for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 33040610

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxin-A (treatment)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.9% sodium-chloride solution (placebo)
Number of subjects: 93
Study: 32079331

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss intervention
Number of subjects: 28
Study: 35562778

Group type: EXPERIMENTAL
Intervention: REALIST ORBCEL‐C (400 × 106 cells or maximal tolerated dose in phase 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 35698954

Group type: EXPERIMENTAL
Intervention: 6h cold-ischemia time (CIT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 12h cold-ischemia time (CIT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both 6h and 12h CIT
Number of subjects: 8
Study: 32224795

Group type: EXPERIMENTAL
Intervention: Multifactor study designs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-treatment trial
Number of subjects: 0
Study: 33508953

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ULDCT) (80 kVp and 5 mAs)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Standard-dose CT (SDCT) (120 kVp and 100 mAs)
Number of subjects: 336
Study: 34553396

Group type: EXPERIMENTAL
Intervention: Low expressed emotion (EE) group
Number of subjects: 121

Group type: COMPARATOR
Intervention: High expressed emotion (EE) group
Number of subjects: 121
Study: 32784263

Group type: EXPERIMENTAL
Intervention: PIVOT with MI communication strategy
Number of subjects: 24
Study: 36141875

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching, 10 stretches total: isometric contraction (3-5 s) followed by stretching (25 s)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static stretching (SS), ankle joint held in maximum dorsiflexion for 30 s, n = 8
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both interventions (PNF and SS)
Number of subjects: 18
Study: 33404325

Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP)
Number of subjects: 101
Study: 32349156

Group type: EXPERIMENTAL
Intervention: Nursing narratives with specific words (e.g., 'urination', 'food supply', 'bowel mobility', 'pain')
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Machine learning techniques for predicting LOS
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Statistical tests on nursing narratives
Number of subjects: 33
Study: 35858264

Group type: EXPERIMENTAL
Intervention: LSVT LOUD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SpeechVive
Number of subjects: 34

Group type: COMPARATOR
Intervention: nontreatment clinical control
Number of subjects: 34
Study: 33914564

Group type: EXPERIMENTAL
Intervention: Rejection exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral social cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Social anxiety (SA)
Number of subjects: 80
Study: 33440262

Group type: EXPERIMENTAL
Intervention: Pump It Up! Personalized T1D Self‐Management Behaviors Feedback Report
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pump It Up! Problem‐Solving Skills intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 0